Chronic Lymphocytic Leukaemia (CLL) is a heterogeneous disease with a clinical course dependent on cytogenetic features. However, in 15-20% of cases both chromosome banding and fluorescence in situ hybridisation analyses do not show any kind of abnormality. With the aim to identify dependable molecular prognostic factors in this subgroup, we performed a comprehensive analysis on 171 patients including genomic arrays (comparative genomic hybridisation and single nucleotide polymorphism), immunoglobulin heavy chain variable region genes (IGHV) status, flow cytometry and targeted sequencing. Genomic arrays detected 73 aberrations in 39 patients (23%). Most frequently, patients had 1 aberration (25/171; 15%), while 14 patients (8%) had at least 2 aberrations. IGHV status was unmutated in 53/171 (31%) patients. SF3B1 was the most frequently mutated gene (26/171 patients; 15%), followed by NOTCH1 (15/171; 9%). At univariate analysis, an adverse impact on time to treatment (TTT) was evident for SF3B1 mutations, higher white blood cell count, higher CLL cells percentage by flow cytometry, CD38 positivity, IGHV unmutated status and at least 2 genomic array abnormalities. Of these, SF3B1 mutations, CLL cells percentage, IGHV unmutated status and number of genomic array aberrations maintained their impact in multivariate analysis. In conclusion, by integrating genomic and molecular data, we identified patients at higher risk for treatment need.
The clinical course of chronic lymphocytic leukaemia (CLL) depends greatly on cytogenetic and molecular features (Dohner et al, 2000; Haferlach et al, 2007; Rossi et al, 2013; Jeromin et al, 2014; Lazarian et al, 2017) . In recent decades, many studies focused on the detection of cytogenetic abnormalities to obtain a detailed biological disease profile. First investigations reported a rate of chromosomal abnormalities of about 50% through chromosome banding analysis (CBA) from CLL cells in cultures (Juliusson & Merup, 1998) . The further introduction of interphase fluorescence in situ hybridisation (FISH) increased the detection rate to 80% and, based on that, a prognostic hierarchical model was built (Dohner et al, 2000) : del(13q) sole; normal karyotype (NK); trisomy 12; del(11q); del(17p). Notably, the outcome worsens from del(13q) sole to del(17p). However, interphase FISH provided information only on a limited number of loci in comparison to CBA, which offers genome-wide information. On the other hand, CBA was limited by the failure of CLL cells to replicate efficiently in vitro. This limit was overcome by improving cultivation techniques, adding CpG-oligonucleotide DSP30 and interleukin 2 to culture medium (Dicker et al, 2006; Put et al, 2009; Heerema et al, 2010) , which raised the detection rate of abnormalities by CBA to more than 80% (Dicker et al, 2006; Haferlach et al, 2007 Haferlach et al, , 2010 Rigolin et al, 2012) . Noteworthy, 20-37% of cases normal by FISH showed aberrations by CBA after stimulation (Haferlach et al, 2007; Rigolin et al, 2012) . However, CBA still suffers some technical drawbacks. Resolution threshold is limited to approximately 5-10 MB and sensitivity is influenced by non-replicative clones or poor chromosome morphology (Gunnarsson et al, 2008; Kjeldsen, 2015) . Therefore, in patients with negative CBA/FISH, some submicroscopic or uncommon cytogenetic abnormalities might not be detected.
The application of sequencing and deep-sequencing approaches has found a set of genes to be recurrently mutated, i.e. TP53, BIRC3, SF3B1, NOTCH1, ATM (Puente et al, 2011 (Puente et al, , 2015 Jeromin et al, 2014; Landau et al, 2015; Lazarian et al, 2017) . TP53 mutation is reported in almost 7% of CLL (Jeromin et al, 2014) and it is the most extensively studied factor, together with del(17p), because it confers the worst progression-free survival (PFS) and overall survival (OS) Rossi et al, 2009) . Similarly, BIRC3 mutations negatively affect patient prognosis . Its incidence among CLL is less than 5%, rising to 24% in fludarabine-refractory patients (Rossi et al, 2012a) . SF3B1 has been found recurrently mutated in nearly 10% of CLL cases (Jeromin et al, 2014) . The lowest rate has been detected in trisomy 12 subset, i.e. 1%, while the del(11q) subgroup has the highest rate, i.e. 20%. Its prognostic importance has been underlined regarding time to treatment (TTT), PFS and OS (Rossi et al, 2011 Mansouri et al, 2013) . NOTCH1 mutations are found in 10-12% of cases, being associated with trisomy 12 (up to 40% in these cases) (Rossi et al, 2012b) , correlating with shorter TTT and OS and risk to Richter transformation (Rossi et al, 2012b; Mansouri et al, 2013) . ATM mutations, found in 10-15% of cases (Guarini et al, 2012; Skowronska et al, 2012) , are strictly related to del(11q) and confer shorter TTT (Guarini et al, 2012; Puente et al, 2015) , PFS and OS (Guarini et al, 2012; Skowronska et al, 2012) , although this should be validated in larger series. Moreover, the CLL mutational landscape is not limited to these genes. Less frequent gene mutations, such as MYD88, XPO1, FBXW7 and POT1 mutations, also relate to clinical outcome and survival (Martinez-Trillos et al, 2014; Landau et al, 2015; Winkelmann et al, 2015) . Combining cytogenetic and molecular data, Rossi et al (2013) developed an integrated model based on FISH analysis and evaluation of SF3B1, BIRC3, NOTCH1 and TP53. Four risk-classes were identified: high-risk, harbouring TP53 and/or BIRC3 mutations or deletions; intermediate-risk, harbouring del(11q) and/or SF3B1 and/or NOTCH1 mutations; low-risk, harbouring normal karyotype (NK) or trisomy 12; very low-risk, harbouring del(13q). The higher the risk, the higher the treatment rate over time and the shorter the OS. Notably, this score was not designed as static, but dynamic. As stated before, clonal selection can occur with a progressive worsening of survival probability.
Nevertheless, although clinical and prognostic implications of defined genetic abnormalities have been well described (Dohner et al, 2000; Haferlach et al, 2007; Hallek et al, 2010) , little is known regarding NK CLL. In the report by Dohner et al (2000) , CLL patients without FISH aberrations (18% of total cohort) showed good prognostic features: Binet stage A in 50% of cases and B symptoms in 16%, median TTT was 4 years and median OS about 10 years. These good features have also been confirmed in the CLL8 trial (Hallek et al, 2010) , comparing immunochemotherapy to chemotherapy, where patients without any abnormality according to the hierarchical model showed an overall response rate of 90% in both treatment groups. However, normal FISH does not translate into normal karyotype. Indeed, in normal FISH subsets, the occurrence of aberrations by CBA determine a negative prognostic impact (Haferlach et al, 2007; Heerema et al, 2010) . Nonetheless, the features of patients with normal FISH and CBA are still unclear.
Although some gene mutations have been related to certain cytogenetic abnormalities , such as NOTCH1 mutations to trisomy 12 or TP53 mutations to del(17p), a specific gene signature for NK CLL has not been defined so far. The molecular evaluation of patients enrolled in the CLL8 trial revealed that patients without any FISH abnormality, according to the hierarchical model, showed a high rate of immunoglobulin heavy chain variable region genes (IGHV) mutated status in more than 50% of patients. Gene mutations were detected in less than half of the cohort with the most frequently mutated gene being SF3B1, followed by NOTCH1 and TP53 .
Given the aforementioned technical limitations in detecting chromosomal abnormalities by CBA and FISH and a missing comprehensive characterization of NK CLL, we applied genomic arrays evaluation together with an extended target-sequencing panel to this specific patient group. Further, we tested whether these findings had prognostic impact.
Patients and methods

Patients
Diagnosis of CLL was based on validated procedures (Dicker et al, 2006; Haferlach et al, 2007; Hallek et al, 2008; Swerdlow et al, 2008; Kern et al, 2009 Kern et al, , 2012 Hallek, 2013; Strati & Shanafelt, 2015) . Selection from 1190 treatment-na€ ıve patients at diagnosis was based on: (i) CLL cells percentage >15% [genomic arrays detection limit for cells carrying an aberration (Schoumans et al, 2016) ]; (ii) NK at CBA and FISH. Among 1158 cases with CLL cells percentage >15%, 187 (16%) showed NK at CBA and FISH. Because of missing data, 16 of them were further excluded and the final cohort comprised 171 patients ( Figure S1A ). General features of patients are available in Table SI . Median age was 65 years (range: 33-83) and 99 patients (58%) were male. Median white blood cell (WBC) count was 19 9 10 9 /l (range: 3Á3-463), median hemoglobin (Hb) was 139 g/l (range: 78-191) and median platelet count was 211 9 10 9 /l (range: 32-533).
Median CLL cells percentage by flow cytometry was 51% (range: 16-94%). All cases with CLL cells lower than 5 9 10 9 /l (n = 38, 22%) had nodal presentation at physical evaluation. ZAP70 and CD38 expression were evaluated by flow-cytometry and cut-offs for prognostic implication were 30% and 20% of positive CLL cells, respectively. Cells were collected after Ficoll procedure and DNA extraction and gene mutations screening were performed as described (Dicker et al, 2006) . Peripheral blood was used in 112 cases and bone marrow was used in 59 cases.
Samples were referred to MLL Munich Leukaemia Laboratory from August 2005 to August 2010. Written informed consent for scientific evaluations was obtained for each patient. The Study was approved by the Internal Review Board and was adherent to the revised tenets of Declaration of Helsinki.
Cytogenetics and FISH
Cytogenetics and FISH were performed for all 1,190 patients as previously described (Dohner et al, 2000; Dicker et al, 2005; Haferlach et al, 2007) and reported according to the International System for Human Cytogenetic nomenclature (McGowan-Jordan et al, 2016) . Including all cases, the median number of analysed metaphases was 20 (range: 2-31). In 12 cases (1%), the number of metaphases was <10 and all of them carried clonal abnormalities.
Interphase FISH was performed with probes for 17p13 (TP53), 13q14 (DLEU), 11q22 (ATM), centromere region of chromosome 12, t(11;14)(q13;q32)(IGH-CCND1), 6q21 and IGH-BCL2 t(14;18) (Metasystems, Altlussheim, Germany), and 13q14 (D13S25, D13S319) (Abbott, Wiesbaden, Germany). According to CBA and FISH data, patients were clustered hierarchically ( Figure S1A ) based on: del(13q) as sole abnormality, trisomy 12, del(11q), del(17p), normal karyotype by CBA and FISH. Other cases not fitting into this model were grouped into subsets: del(6q); del(13q) with additional aberrations; other abnormalities at CBA; and complex karyotype with at least 3 clonal chromosome abnormalities. (Dohner et al, 2000; Dicker et al, 2005; Haferlach et al, 2007) .
Genomic arrays
Genomic arrays were performed on the final cohort of 171 patients using SurePrint G3 International Standards for Cytogenomic Arrays (ISCA) comparative genomic hybridization and single nucleotide polymorphism (CGH + SNP) Microarray 4 9 180 K (Agilent, Waldbronn, Germany) according to the manufacturer's instructions. Slides were scanned at 2-lm resolution on SureScan Dx Microarray Scanner (Agilent). Nexus Copy Number Software v. 7.5 (BioDiscovery, El Segundo, CA, USA) was used to analyse chromosomal patterns. Copy number calls were performed using the default SNP-FASST2 segmentation algorithm. The data were submitted to the Gen Expression Omnibus (GEO) database (accession number GSE103306).
We referred on genomic aberrations if greater than 50 kb and not reported in the database of genomic variants or located in non-coding regions (Lee et al, 2007; Schoumans et al, 2016) . Aberrations were distinct as copy neutral loss of heterozygosis (CN-LOH), defined with a size of at least 10 MB as interstitial or telomeric according to the involved region, and copy number abnormalities (CNA), defined in case of gains or losses (O'Keefe et al, 2010; Grossmann et al, 2013; Schoumans et al, 2016) . Aberrations by genomic array were described according to the International System for Human Cytogenetic Nomenclature (McGowan-Jordan et al, 2016) . When feasible, aberrations were confirmed with additional FISH probes: 4q24 (TET2), 13q14 (RB1), 21q22 (RUNX1), 5p15/5q31, 3q26 (MECOM), FGFR3-IGH t(4;14), ZFP36L1-ACTN1, HOXA9 (Metasystems, Altlussheim, Germany), 12p13 (ETV6), CEP#3, CEP#9 (CDNK2A) (Abbott, Wiesbaden, Germany), 10q24 (TLX1) (Cytocell, Cambridge, UK).
Molecular analysis
Sanger sequencing was performed using BigDye Term v1.1 cycle sequencing chemistry (Applied Biosystems, Weiterstadt, Germany), while amplicon next-generation deep-sequencing with MiSeq Instrument (Illumina, San Diego, CA, USA) or massively parallel Titanium amplicon NGS technology (454 Life Sciences, Branford, CT) as previously reported Jeromin et al, 2014) . TP53 re-sequencing research microarray, denaturing high-performance liquid chromatography (DHPLC), in combination with direct DNA sequencing or NGS, were also used to detect TP53 mutations (Dicker et al, 2005 . Sensitivity was 3% for NGS and DHPLC-TP53 microarray and 10% for Sanger sequencing. IGHV mutational status was analysed as previously published (Dicker et al, 2006) ; unmutated status was defined by sequence identity ≥98%.
Mutation screening was performed for ATM, BIRC3, BRAF, FBXW7, KLHL6, KRAS, NRAS, NOTCH1, POT1, SF3B1, TP53, XPO1, ITPKB, EGR2, HIST1H1E, RIPK1, DDX3X, MAPK1, RPS15 and CCND2 genes. Details on used primers can be found in Table SII .
Statistical analysis
For descriptive statistics, data is reported as median and range or average and standard deviation. Dichotomous variables were compared using v 2 -test and continuous variables using Student's t test or Mann-Whitney Test in case of parametric and non-parametric statistics, respectively. KaplanMeier method was applied for TTT and OS curves and results were analysed applying two-sided log-rank test. TTT was calculated from diagnosis to treatment initiation or last follow-up at which patients were known to be untreated. OS was calculated from diagnosis to last follow-up or death. Cox univariate analysis for Hazard Ratio evaluation regarding TTT and OS was performed for the relevant parameter. Multiple comparison for adjusted P values was than applied using the Benjamini -Hochberg test. Cox multivariate analysis included parameters significant (P < 0Á05) at univariate analysis and multiple comparison testing. Moreover, in order to avoid overfitting of the model, WBC count, Hb and platelet count data were not entered in the multivariate analysis, also because these data were not available for 10 patients. Genes were taken into account only if mutated in at least 5 cases (i.e. 3% of the studied population). Moreover, to avoid repetition, we selected, among genomic array data, the occurrence of at least 2 aberrations. Spearman's rank correlation test was applied to assess the relationship between two variables.
All statistical tests were two-sided, and statistical significance was set at P < 0Á05. Statistical analyses were performed using SPSS version 19.0.0 (IBM Corporation, Armonk, NY, USA.
Results
Genomic array detected aberrations in a subset of cases
In 39 patients out of 171 (23%), we detected 73 aberrations (60 CNA and 13 CN-LOH) ( Figure S2A ; Table SIII ). At least 20 metaphases were analysed at CBA, except for three cases showing 10, 15 and 17 metaphases. No differences in evaluated metaphase numbers were detected between abnormal versus normal genomic array groups (20 AE 2 vs. 20 AE 2 metaphases).
Median CNA size was 2Á5 MB (range: 0Á16-198). In 11 of 171 patients (6%), we identified 19 aberrations (29% of total number) greater than 10 MB. These 19 abnormalities should, in principle, have been detected by CBA. We ascribed the not informative CBA to low in vitro replication of the abnormal clone in five patients (8 abnormalities) and to poor chromosome morphology in 6 cases (11 abnormalities). Notably, in all 11 cases, the number of analysed metaphases at CBA was 20.
Deletions (30/73; 41%) were detected in 21 of 171 patients (12%); median size was 2Á3 MB (range: 0Á38-97), with 11/30 (37%) greater than 10 MB. Gains (30/73; 41%) were identified in 15 patients (9%); median size was 1Á9 MB (range: 0Á16-198) and 8/30 (27%) aberrations were greater than 10 MB. CN-LOH occurred at lower frequency (13/73; 18%). Median size was 39 MB (range: 11Á3-110) and 9 out of 13 (69%) were telomeric ( Fig 1A; Table SIV ). The majority of patients (25/ 171; 15%) had one aberration, 10 patients (6%) two aberrations and 4 (2%) more than two ( Figure S2B ). Recurrent aberrations ( Figures S2C-D In eight cases, gains and losses were detected simultaneously. CN-LOH were detected with gains in one case and with losses in another case (Fig 1B) . FISH analysis, with probes available for 12 out of 60 regions involved by aberrations, confirmed aberrations identified by genomic arrays in all cases, except for two cases with del(13q) undetectable by FISH (Patients 29 and 36) ( Table SV) .
Gene mutations and IGHV status
Seventy-one patients out of 171 (42%) showed mutations in the following genes: SF3B1 (n = 26, 15%), NOTCH1 Organogram showing the genomic array workflow in NK CLL patients. Array investigation was performed in 171 patients. According to findings, patients were clustered into cases with normal (n = 132) or aberrant (n = 39) array data. The aberrations (73 in 39 patients) were consecutively classified as deletions (30 in 21 patients), gains (30 in 15 patients) or copy neutralloss of heterozygosity (CN-LOH; 13 in 13 patients). Finally, Copy Number Changes, i.e. gains and losses, were divided into microscopic (<10 MB) (19 losses in 14 patients; 22 gains in 11 patients) and macroscopic (at least 10 MB) (11 losses in 10 patients and 8 gains in 6 patients), while CN-LOH were divided into telomeric (n = 9) and interstitial (n = 4). n, indicates the number of patients; #, indicates the number of aberrations. (B) Venn diagram showing the occurrence of the different copy number abnormalities, i.e. losses, gains and CN-LOH and their simultaneous incidence among the patients with abnormal genomic array.
(n = 15, 9%), ATM (n = 5; 3%); TP53 (n = 5; 3%); KLHL6 (n = 5; 3%); MYD88 (n = 5; 3%); XPO1 (n = 5; 3%); FBXW7 (n = 3; 2%); POT1 (n = 2; 1%); NRAS (n = 3; 2%); DDX3X (n = 2; 1%); KRAS (n = 2; 1%); ITPKB (n = 1; 0Á6%); BRAF (n = 1; 0Á6%); HIST1H1E (n = 1; 0Á6%), CCND2 (n = 1, 0Á6%) and no mutation in RPS15, MAPK1, EGR2, RIPK1 and BIRC3 ( Figure S4 ; Table SVI ). Eleven patients (6%) had 2 simultaneous gene mutations and 1 patient had 3 (i.e. ATM, SF3B1 and XPO1). The list of variants of unknown significance is reported in Table SVII . Unmutated IGHV status (IGHV-U) was detected in 53 (31%) patients and related to poor clinical features, such as higher CLL cells percentage, ZAP70 positivity and CD38 positivity (Table SVIII) . IGHV-U related not only to NOTCH1 (12/53, 23% vs. 3/ 118, 2Á5%; P < 0Á001) but also to POT1 (2/53, 3Á8% vs. 0; P = 0Á03) and XPO1 (4/53, 7Á5% vs. 1/118, 0Á8%; P = 0Á016) mutations, although the statistics are less strong for POT1 and XPO1 due to the low mutation rate. The comparison between bone marrow (59 patients) and peripheral blood (112 patients) did not show any relevant difference (Table SIX) .
BCR stereotypy was detected in 13 patients out of 171 (8%). Three were in cluster CLL1 (two of them showing NOTCH1 mutation), 4 in CLL2 (1 with SF3B1 mutation alone, 1 with SF3B1 and ATM and 1 with SF3B1, ATM and XPO1 mutations), 2 in CLL4 (showing no mutations), 2 in CLL8 (1 with NOTCH1 and XPO1 mutations and 1 with BRAF mutation), 1 in CLL201 (with KLHL6 mutation) and 1 in CLL202 (showing ATM and NOTCH1 mutations).
Integration of mutational and genomic array findings
Patients with abnormalities identified by genomic arrays, compared to patients without aberrations, did not differ in age, gender, WBC count, Hb level and platelet count. Patients with any genomic aberration had higher percentages of CLL cells (60 AE 21% vs. 49 AE 19%, P = 0.002) and there was a higher rate of patients with CD38-positive cells ≥30% (44% vs. 16%, P = 0Á001), ZAP70 + ≥20% (54% vs. 34%, P = 0Á03) and IGHV-U (51% vs. 25%, P = 0Á002) (Table I) . Notably, the higher the percentage of CLL cells, the higher the percentage of patients harbouring genomic array aberrations, with genomic array aberrations increasing from 5% for patients with 15-25% CLL cells up to 43% for patients with at least 75% CLL cells in flow-cytometry (P = 0Á001). SF3B1 mutations were related to occurrence of genomic gains. Out of 26 patients with mutated SF3B1, 5 (19%) showed gains versus 10 out of 145 SF3B1 (wild-type (7%) (P = 0Á041). NOTCH1 mutations did not relate to genomic array aberrations in general. Interestingly, one of them showed a 9q CN-LOH (involving NOTCH1) with a mutation burden of 79% (homozygous status). All 5 TP53 mutated patients showed no genomic array aberrations. No correlation occurred between genomic array findings and ATM, MYD88 and XPO1 mutations. The low frequency of other mutated genes did not provide a reliable sample size for statistics.
Prognostic evaluation
Median follow-up was 5Á4 years (95% confidence interval [CI] 5Á0-5Á8 years) and 10-year OS was 74%. Forty-eight patients (28%) underwent treatment and median TTT was 9Á2 years (Figure S1B-C) .
In Kaplan-Meier analysis (Fig 2) , TTT was shorter in cases with CD38 positivity (median: 6Á1 years vs. 9Á2 years, P = 0Á001), SF3B1 mutation (6Á1 years vs. 10Á7 years, P = 0Á005) and IGHV-U (4Á8 years vs. not reached median, P < 0Á001) but not in cases with NOTCH1 mutations. Moreover, the number of mutations did not show an impact on TTT. Occurrence of any genomic array aberration did not confer an augmented risk of treatment compared to patients showing no aberrations (median TTT 10Á2 years vs. 9Á2 years; P = 0Á047). However, when clustering patients according to the number of aberrations we noticed that patients with at least 2 aberrations had a significantly lower median TTT than patients with only one or without aberration (0Á8 years vs. 9Á2 years vs. 10Á2 years, P = 0Á001). According to aberration type, TTT was lower in patients with gains than in patients without (2Á3 years vs. 9Á2 years, P = 0Á004), while the occurrence of losses or CN-LOH did not influence the TTT. Moreover, TTT was not influenced by other parameters ( Figure S5 ). At Cox multivariate analyses, an independent impact on TTT was confirmed for: percentage of CLL cells (Hazard ratio [HR] 1Á2 per 10% increase; 95% CI 1Á0-1Á4; P = 0Á02); IGHV-U (HR 4Á4; 95% CI 2Á3-8Á4; P < 0Á001); SF3B1 mutations (HR 2Á2; 95% CI 1Á1-4Á2; P = 0Á021) and occurrence of at least 2 genomic array aberrations (HR 3Á1; 95% CI 1Á4-7Á3; P = 0Á007) (Table II) .
Based on the multivariate analysis, we clustered patients further according to the number of independent risk factors, considering IGHV-U, SF3B1 mutation and occurrence of at least 2 genomic array aberrations (Fig 3) . The low risk cluster, i.e. 98 patients (57%) without risk factors, did not reach the median TTT. Patients at intermediate risk (n = 56; 33%), i.e. patients with 1 risk factor, showed a median TTT of 6Á5 years. Patients at high risk (n = 17; 10%), i.e. with at least 2 risk factors, showed a median TTT of 9 months (P < 0Á001).
Regarding overall survival (OS), neither genomic array aberrations nor gene mutations showed an impact. After the Benjamini-Hochberg correction test, only age retained a prognostic relevance (HR 2Á8 per decade; 95% CI 1Á6-4Á9; P = 0Á02) (Table III) .
Discussion
Both chromosome banding and FISH analyses do not show abnormalities in 15-20% of CLL and these patients are reported as having a normal karyotype (Dohner et al, 2000; Haferlach et al, 2007) . Given that these cases are usually diagnosed at early clinical stage, molecular parameters allowing prediction of clinical course independently from clinical assessment are warranted (Gentile et al, 2014) . With the aim to better understand the molecular features of this subgroup and the possible prognostic factors, we applied a genomic array karyotyping together with target-sequencing analysis.
To the best of our knowledge, this is the first analysis on patients not harbouring any aberrations by both FISH and CBA. In our analysis, more than 20% of patients without aberrations in CBA and FISH showed abnormalities by genomic arrays and one-third of them showed at least two aberrations. Thus, genomic array can detect additional aberrations in patients otherwise considered with a normal karyotype. In addition, we integrated these findings with an extended genemutation panel. SF3B1 and NOTCH1 were found to be the most frequently mutated genes, with a mutation rate of 15% and 9%, respectively, while TP53 and MYD88 were rarely mutated. This is in line with our previous study (Jeromin et al, 2014) where patients with normal FISH, not accounting for CBA analysis, showed a mutation rate for SF3B1 of 15% and for NOTCH1 of 7%, while MYD88 and TP53 were also rarely mutated (2% and 5% respectively). As a matter of fact, 100 patients (58%) from our actual series did not show any gene mutation, considering the explored panel. Of these patients, 21 showed abnormalities by genomic array. However, 79 patients (46% of the cohort) did not show any event (Fig 4) . 
(per 10 9 10 9 /l increase)
Number of aberrations (<2 vs. ≥2) Moreover, by clustering patients according to the number of genomic array aberrations , we found a very short TTT of less than 1 year for patients with at least 2 aberrations and a longer TTT of 9-10 years for patients with no or only 1 aberration. The prognostic impact in terms of TTT was also retained in a multivariate analysis, together with SF3B1 mutations, IGHV-U status and percentage of CLL cells. As an additional finding, the rate of genomic array aberrations increased with the percentage of CLL cells detected at flow-cytometry. In our opinion, this may be due to either the biology of disease or technical reasons (Schoumans et al, 2016) , because subclonal aberrations may be missed in cases of lower tumour burden. Patients with higher tumour load, i.e. higher percentage of CLL cells, % untreated are likely to have more advanced disease and a more aggressive behaviour showing more aberrations and subclones at genomic levels (Nadeu et al, 2018) . Supporting this hypothesis, the multivariate analysis regarding TTT showed that the number of genomic array aberrations was related to a worse outcome independently from the percentage of CLL cells. The impact of genomic arrays has been already investigated in patients with normal FISH, without CBA analysis (Mian et al, 2013) . In this study, the occurrence of aberrations at genomic array conferred a shorter TTT, particularly in patients with mutated IGHV status and patients at early stage disease. Thus, in line with data from literature, we were able to identify lesions not covered by a standard FISH panel, overcoming the limited resolution of CBA and need for cell replication, especially in a subset of patients whose disease had a more aggressive behaviour.
This finding would be even more important in the era of new drugs, where IGHV unmutated status and del(17p) or TP53 mutation seem to have a minor impact on treatment outcome Woyach et al, 2014; O'Brien et al, 2016; Brown et al, 2018) . Indeed, new mutations have been discovered to be related to refractoriness, i.e. inactivating mutations in the Bruton tyrosine kinase (BTK) gene and gain-of-function mutations in PLCG2 gene. However, BTK and PLCG2 mutations arise after treatment and could not be detected ahead, while genomic instability is a dependable risk factor for treatment failure evaluable upfront (Thompson et al, 2014 (Thompson et al, , 2015 . In this perspective, the possibility that the genomic evaluation could address the treatment should be a matter for further studies.
In conclusion, based on our findings, genomic arrays can detect aberrations in 23% of patients with a normal karyotype based on chromosome banding analysis and FISH. The number of aberrations detected by genomic arrays, together with SF3B1 mutations and IGHV-U status, can help stratifying patients according to need for treatment. Although we are conscious that a validation set is mandatory to confirm this model, we think that this integrated approach would add significant information in predicting the clinical course of patients with normal karyotype based on FISH and chromosome banding analysis. 
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